Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725752 | 0.91 | PDGFRB (0.48) | KDM4ELMNAHTTMEN1KMT2A | |
| SCHEMBL10072172 | 0.85 | KDM4E (0.64) | KDM4EMAPTNPSR1LMNAHTT | |
| SCHEMBL27761143 | 0.84 | HRH4 (0.61) | KDM4EMAPTNPSR1LMNAHTT | |
| SCHEMBL10072150 | 0.83 | ENPP1 (0.49) | KDM4EMAPTNPSR1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL9270707 | 0.82 | HRH4 (0.60) | KDM4EMAPTNPSR1LMNAHTT | |
| SCHEMBL2722449 | 0.80 | EGFR (0.63) | KDM4EMAPTNPSR1HTTHSD17B10 | |
| SCHEMBL4178072 | 0.78 | PRKDC (0.52) | NPSR1LMNAHTTHIF1ATSHR | |
| SCHEMBL1585491 | 0.78 | HTT (0.51) | NPSR1LMNAHTTMEN1KMT2A | |
| SCHEMBL14407961 | 0.78 | HTR7 (0.68) | AURKAAURKBHTR7 | |
| SCHEMBL3856130 | 0.77 | AKT1 (0.50) | KDM4EMAPTNPSR1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153997-B | Quinazoline derivatives | MERCK PATENT GMBH | 2015-04-29 | — | — | CN | disclosed |
| US-9006255-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006255-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006255-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| EP-2632923-B1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2632923-B1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2632923-A1 | QUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20130210819-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210819-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210819-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| CN-103153997-A | Quinazoline derivatives | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | disclosed |
| WO-2012055466-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055466-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210819-A1 | QUINAZOLINE DERIVATIVES | RAB1A, PIK3R5, PIK3R1 | KDM4E 4345/4885MAPT 3452/4885NPSR1 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.